
Ultragenyx Pharmaceutical Inc.: shareholders and insiders
Price
$16.48
November 20, 2026Market cap $1.7B
What Ploutos Investor adds for Ultragenyx Pharmaceutical
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 21, 2025 to Oct 19, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$3.8M
9 people
From Nov 21, 2025 to Nov 21, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan35%
- The rest65%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 21, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $3.7M by 9 people
- 2025: no buys, sold $115.0K by 2 people
- 2026: no buys, sold $3.7M by 9 people
- Oct 15, 2026Howard HornChief Financial OfficerKind
- Sep 15, 2026Theodore Alan HuizengaSVP, Chief Accounting OfficerKind10b5-1
- Sep 3, 2026Theodore Alan HuizengaSVP, Chief Accounting OfficerKind
- Aug 3, 2026Karah Herdman ParschauerEVP and Chief Legal OfficerKind10b5-1
- Aug 3, 2026Howard HornChief Financial OfficerKind10b5-1
- Jul 1, 2026Howard HornChief Financial OfficerKind10b5-1
- Jun 15, 2026Corazon (Corsee) D. SandersDirectorKind
- Jun 15, 2026Karah Herdman ParschauerEVP and Chief Legal OfficerKind10b5-1
- Jun 1, 2026Howard HornChief Financial OfficerKind10b5-1
- May 18, 2026Shehnaaz SulimanKind10b5-1
- May 5, 2026Eric CrombezEVP and Chief Medical OfficerKind
- May 1, 2026Howard HornChief Financial OfficerKind10b5-1
- Apr 1, 2026Howard HornChief Financial OfficerKind10b5-1
- Mar 10, 2026Karah Herdman ParschauerEVP and Chief Legal OfficerKind
- Mar 6, 2026Karah Herdman ParschauerEVP and Chief Legal OfficerKind
- Mar 3, 2026Howard HornChief Financial OfficerKind10b5-1
- Mar 2, 2026Eric CrombezEVP and Chief Medical OfficerKind
- Mar 2, 2026Howard HornChief Financial OfficerKind10b5-1
- Mar 2, 2026Howard HornChief Financial OfficerKind10b5-1
- Mar 2, 2026Theodore Alan HuizengaSVP, Chief Accounting OfficerKind
- Mar 2, 2026Karah Herdman ParschauerEVP and Chief Legal OfficerKind
- Mar 2, 2026Emil D KakkisPresident & CEOKind
- Mar 2, 2026Erik HarrisEVP & Chief Commercial OfficerKind
- Mar 2, 2026John Richard PinionKind
- Feb 2, 2026Howard HornChief Financial OfficerKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 15, 2026 | Howard HornChief Financial Officer | 7,066 | $15.27 | $107.9K | Form 4 | |
| Sep 15, 2026 | Theodore Alan HuizengaSVP, Chief Accounting Officer | 10b5-1 | 1,283 | $13.57 | $17.4K | Form 4 |
| Sep 3, 2026 | Theodore Alan HuizengaSVP, Chief Accounting Officer | 161 | $13.99 | $2.3K | Form 4 | |
| Aug 3, 2026 | Karah Herdman ParschauerEVP and Chief Legal Officer | 10b5-1 | 1,900 | $24.92 | $47.3K | Form 4 |
| Aug 3, 2026 | Howard HornChief Financial Officer | 10b5-1 | 4,696 | $24.92 | $117.0K | Form 4 |
| Jul 1, 2026 | Howard HornChief Financial Officer | 10b5-1 | 4,698 | $33.13 | $155.6K | Form 4 |
| Jun 15, 2026 | Corazon (Corsee) D. SandersDirector | 2,000 | $25.05 | $50.1K | Form 4 | |
| Jun 15, 2026 | Karah Herdman ParschauerEVP and Chief Legal Officer | 10b5-1 | 1,899 | $24.62 | $46.8K | Form 4 |
| Jun 1, 2026 | Howard HornChief Financial Officer | 10b5-1 | 4,653 | $23.77 | $110.6K | Form 4 |
| May 18, 2026 | Shehnaaz Suliman | 10b5-1 | 5,740 | $25.12 | $144.2K | Form 4 |
| May 5, 2026 | Eric CrombezEVP and Chief Medical Officer | 344 | $24.96 | $8.6K | Form 4 | |
| May 1, 2026 | Howard HornChief Financial Officer | 10b5-1 | 4,683 | $24.90 | $116.6K | Form 4 |
| Apr 1, 2026 | Howard HornChief Financial Officer | 10b5-1 | 4,683 | $20.97 | $98.2K | Form 4 |
| Mar 10, 2026 | Karah Herdman ParschauerEVP and Chief Legal Officer | 3,508 | $22.67 | $79.5K | Form 4 | |
| Mar 6, 2026 | Karah Herdman ParschauerEVP and Chief Legal Officer | 6,018 | $21.40 | $128.8K | Form 4 | |
| Mar 3, 2026 | Howard HornChief Financial Officer | 10b5-1 | 1,635 | $22.40 | $36.6K | Form 4 |
| Mar 2, 2026 | Eric CrombezEVP and Chief Medical Officer | 7,029 | $22.80 | $160.3K | Form 4 | |
| Mar 2, 2026 | Howard HornChief Financial Officer | 10b5-1 | 3,119 | $22.54 | $70.3K | Form 4 |
| Mar 2, 2026 | Howard HornChief Financial Officer | 10b5-1 | 5,290 | $22.80 | $120.6K | Form 4 |
| Mar 2, 2026 | Theodore Alan HuizengaSVP, Chief Accounting Officer | 1,632 | $22.80 | $37.2K | Form 4 | |
| Mar 2, 2026 | Karah Herdman ParschauerEVP and Chief Legal Officer | 8,135 | $22.80 | $185.5K | Form 4 | |
| Mar 2, 2026 | Emil D KakkisPresident & CEO | 54.4K | $22.80 | $1.2M | Form 4 | |
| Mar 2, 2026 | Erik HarrisEVP & Chief Commercial Officer | 10.5K | $22.80 | $240.3K | Form 4 | |
| Mar 2, 2026 | John Richard Pinion | 10.0K | $22.80 | $228.7K | Form 4 | |
| Feb 2, 2026 | Howard HornChief Financial Officer | 10b5-1 | 3,061 | $23.56 | $72.1K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 1, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by RARE's officers and directors from 2014 up to November 20, 2025, 12 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 7 more, back to 2014
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Vanguard Portfolio ManagementShare of class8.60%
- BlackRock, Inc.Share of class8.30%
- RTW Investments, LPwith 1 more personShare of class7.90%
- State Streetwith 1 more personShare of class7.60%
- AQR Capital Management, LLCwith 1 more personShare of class6.66%
- Madison Avenue International LPwith 5 more personsShare of class6.40%
- Vanguard Capital ManagementShare of class5.13%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Vanguard Portfolio Management | 8.60% | 8.48M | Oct 30, 20263 filings since Apr 29, 2026 | 13G/A | |
| BlackRock, Inc. | 8.30% | 8.14M | Jul 30, 20262 filings since Apr 24, 2025 | 13G/A | |
| RTW Investments, LPwith 1 more person | 7.90% | 7.80M | Aug 14, 2026 | 13G | |
| State Streetwith 1 more person | 7.60% | 7.54M | Nov 10, 20263 filings since May 12, 2026 | 13G | |
| AQR Capital Management, LLCwith 1 more person | 6.66% | 6.56M | Aug 13, 2026 | 13G | |
| Madison Avenue International LPwith 5 more persons | 6.40% | 6.31M | Oct 20, 2026 | 13G | |
| Vanguard Capital Management | 5.13% | 5.06M | Jul 31, 2026 | 13G |
Fell to 5% or less (4)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Point72 (Cohen)In the quarter
- Millennium Mgmt (Englander)In the quarter+100%
- Renaissance TechnologiesIn the quarter
- D.E. ShawIn the quarter-48%
- Bridgewater (Dalio)In the quarter
- Citadel Advisors (Griffin)In the quarter+69%
- AQR CapitalIn the quarter-90%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Point72 (Cohen) | 844.4K | $13M | 0.02% | |
| Millennium Mgmt (Englander) | 1.52M | +100% | $23M | 0.02% |
| Renaissance Technologies | – | – | 0.02% | |
| D.E. Shaw | 892.1K | -48% | $13M | 0.01% |
| Bridgewater (Dalio) | 57.1K | $900.0K | 0.00% | |
| Citadel Advisors (Griffin) | 356.7K | +69% | $5.4M | 0.00% |
| AQR Capital | 633.4K | -90% | $9.5M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 19.8% of its shares outstanding were held short, -1.0% since the report before.
- Shares held short
- 20.15M
- 19.8%
- Since the report before20.35M on Sep 30, 2026
- -1.0%
- 5.2
- 3.89M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 63%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 4.16M
- Nov 15, 2023: Shares held short 3.50M
- Nov 30, 2023: Shares held short 3.24M
- Dec 15, 2023: Shares held short 3.34M
- Dec 29, 2023: Shares held short 4.06M
- Jan 12, 2024: Shares held short 4.12M
- Jan 31, 2024: Shares held short 3.41M
- Feb 15, 2024: Shares held short 3.56M
- Feb 29, 2024: Shares held short 3.87M
- Mar 15, 2024: Shares held short 3.78M
- Mar 28, 2024: Shares held short 3.92M
- Apr 15, 2024: Shares held short 4.38M
- Apr 30, 2024: Shares held short 4.65M
- May 15, 2024: Shares held short 4.34M
- May 31, 2024: Shares held short 4.47M
- Jun 14, 2024: Shares held short 5.04M
- Jun 28, 2024: Shares held short 4.24M
- Jul 15, 2024: Shares held short 4.36M
- Jul 31, 2024: Shares held short 4.23M
- Aug 15, 2024: Shares held short 3.85M
- Aug 30, 2024: Shares held short 3.51M
- Sep 13, 2024: Shares held short 3.61M
- Sep 30, 2024: Shares held short 2.89M
- Oct 15, 2024: Shares held short 3.16M
- Oct 31, 2024: Shares held short 3.18M
- Nov 15, 2024: Shares held short 3.35M
- Nov 29, 2024: Shares held short 3.38M
- Dec 13, 2024: Shares held short 3.71M
- Dec 31, 2024: Shares held short 4.02M
- Jan 15, 2025: Shares held short 4.25M
- Jan 31, 2025: Shares held short 4.16M
- Feb 14, 2025: Shares held short 4.28M
- Feb 28, 2025: Shares held short 4.59M
- Mar 14, 2025: Shares held short 4.81M
- Mar 31, 2025: Shares held short 4.53M
- Apr 15, 2025: Shares held short 5.46M
- Apr 30, 2025: Shares held short 5.54M
- May 15, 2025: Shares held short 5.89M
- May 30, 2025: Shares held short 5.55M
- Jun 13, 2025: Shares held short 6.08M
- Jun 30, 2025: Shares held short 6.82M
- Jul 15, 2025: Shares held short 8.80M
- Jul 31, 2025: Shares held short 7.64M
- Aug 15, 2025: Shares held short 8.41M
- Aug 29, 2025: Shares held short 8.32M
- Sep 15, 2025: Shares held short 7.95M
- Sep 30, 2025: Shares held short 7.65M
- Oct 15, 2025: Shares held short 8.69M
- Oct 31, 2025: Shares held short 7.14M
- Nov 14, 2025: Shares held short 7.83M
- Nov 28, 2025: Shares held short 8.87M
- Dec 15, 2025: Shares held short 8.60M
- Dec 31, 2025: Shares held short 8.02M
- Jan 15, 2026: Shares held short 8.86M
- Jan 30, 2026: Shares held short 9.10M
- Feb 13, 2026: Shares held short 9.86M
- Feb 27, 2026: Shares held short 9.60M
- Mar 13, 2026: Shares held short 9.93M
- Mar 31, 2026: Shares held short 11.41M
- Apr 15, 2026: Shares held short 12.09M
- Apr 30, 2026: Shares held short 13.67M
- May 15, 2026: Shares held short 13.98M
- May 29, 2026: Shares held short 14.70M
- Jun 15, 2026: Shares held short 14.31M
- Jun 30, 2026: Shares held short 16.22M
- Jul 15, 2026: Shares held short 13.44M
- Jul 31, 2026: Shares held short 14.96M
- Aug 14, 2026: Shares held short 15.89M
- Aug 31, 2026: Shares held short 17.14M
- Sep 15, 2026: Shares held short 16.57M
- Sep 30, 2026: Shares held short 20.35M
- Oct 15, 2026: Shares held short 20.15M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading35.2% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 35.2% of the shares in the reported trades were short sales, against 47.0% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 35.2%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 47.0%
- Change
- -11.8 pts
- Short sales a dayon average, of 1.55M shares
- 547.8K
- More than atof 3,666 US-listed companies, same days
- 11%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 40.5%
- Oct 15, 2026: Short sales 42%
- Oct 16, 2026: Short sales 40.2%
- Oct 19, 2026: Short sales 39.6%
- Oct 20, 2026: Short sales 47.9%
- Oct 21, 2026: Short sales 48.7%
- Oct 22, 2026: Short sales 39.9%
- Oct 23, 2026: Short sales 49.2%
- Oct 26, 2026: Short sales 66.4%
- Oct 27, 2026: Short sales 56.7%
- Oct 28, 2026: Short sales 50%
- Oct 29, 2026: Short sales 37.7%
- Oct 30, 2026: Short sales 46.8%
- Nov 2, 2026: Short sales 42%
- Nov 3, 2026: Short sales 41.2%
- Nov 4, 2026: Short sales 44.5%
- Nov 5, 2026: Short sales 33%
- Nov 6, 2026: Short sales 25.9%
- Nov 9, 2026: Short sales 35.2%
- Nov 10, 2026: Short sales 44%
- Nov 11, 2026: Short sales 43.6%
- Nov 12, 2026: Short sales 26.4%
- Nov 13, 2026: Short sales 39.9%
- Nov 16, 2026: Short sales 46.4%
- Nov 17, 2026: Short sales 12.4%
- Nov 18, 2026: Short sales 34.7%
- Nov 19, 2026: Short sales 32.4%
- Nov 20, 2026: Short sales 40.5%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Emil D KakkisPresident & CEODirectly659.0K
- Thomas Richard KassbergCBO & EVPDirectly265.2K
- Eric CrombezEVP and Chief Medical OfficerDirectly111.2K
- John Richard PinionSee RemarksDirectly110.0K
- Karah Herdman ParschauerEVP and Chief Legal OfficerDirectly92.6K
- Erik HarrisEVP & Chief Commercial OfficerDirectly89.5K
- Howard HornChief Financial OfficerDirectly89.2K
- Theodore Alan HuizengaSVP, Chief Accounting OfficerDirectly67.9K
- Shehnaaz SulimanDirectorDirectly28.0K
- Corazon (Corsee) D. SandersDirectorDirectly21.1K
- Matthew K FustDirectorDirectly14.9K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Emil D KakkisPresident & CEO | 659.0K | 2.16M | Mar 2, 2026 | Form 4 |
| Thomas Richard KassbergCBO & EVP | 265.2K | – | Mar 3, 2025 | Form 4 |
| Eric CrombezEVP and Chief Medical Officer | 111.2K | – | May 5, 2026 | Form 4 |
| John Richard PinionSee Remarks | 110.0K | – | Mar 2, 2026 | Form 4 |
| Karah Herdman ParschauerEVP and Chief Legal Officer | 92.6K | – | Aug 3, 2026 | Form 4 |
| Erik HarrisEVP & Chief Commercial Officer | 89.5K | – | Mar 2, 2026 | Form 4 |
| Howard HornChief Financial Officer | 89.2K | – | Oct 15, 2026 | Form 4 |
| Theodore Alan HuizengaSVP, Chief Accounting Officer | 67.9K | – | Sep 15, 2026 | Form 4 |
| Shehnaaz SulimanDirector | 28.0K | – | May 18, 2026 | Form 4 |
| Corazon (Corsee) D. SandersDirector | 21.1K | – | Jun 15, 2026 | Form 4 |
| Matthew K FustDirector | 14.9K | – | Mar 7, 2024 | Form 4 |
A lower bound: it counts only the 11 officers and directors with a market trade since Nov 22, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund1.14%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.63%
- IBBiShares Biotechnology ETFWeight in the fund0.23%
- IWNiShares Russell 2000 Value ETFWeight in the fund0.11%
- FESMFidelity Enhanced Small Cap Core ETFWeight in the fund0.10%
- IWMiShares Russell 2000 ETFWeight in the fund0.10%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.09%
- VBKVanguard Small-Cap Growth Index FundWeight in the fund0.09%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.08%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.05%
20 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 304
- Q4 2025: Managers 288
- Q1 2026: Managers 301
- Q2 2026: Managers 310
Institutional investors by quarter
The fund managers holding RARE, quarter by quarter, from Q1 2014 to Q2 2025, 46 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 310 managers held 107M shares, worth $3.6B. During the quarter 58 opened a position, 49 closed one, 113 added and 98 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+46%
- Rtw InvestmentsIn the quarter+114%
- Vanguard Portfolio ManagementIn the quarter+26%
- AQR CapitalIn the quarter+43%
- State StreetIn the quarter+23%
- Vanguard Capital ManagementIn the quarter+2.5%
- Two Sigma InvestmentsIn the quarter+64%
- Sands Capital ManagementIn the quarter-1.7%
- Jacobs Levy Equity ManagementIn the quarter+105%
- Frontier Capital ManagementIn the quarter+30%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 10.65M | +46% | $356M |
| Rtw Investments | 7.80M | +114% | $260M |
| Vanguard Portfolio Management | 6.79M | +26% | $227M |
| AQR Capital | 6.56M | +43% | $214M |
| State Street | 6.16M | +23% | $206M |
| Vanguard Capital Management | 4.30M | +2.5% | $143M |
| Two Sigma Investments | 3.62M | +64% | $121M |
| Sands Capital Management | 3.16M | -1.7% | $105M |
| Jacobs Levy Equity Management | 2.94M | +105% | $98M |
| Frontier Capital Management | 2.85M | +30% | $95M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Ultragenyx Pharmaceutical's filings show?
Who buys and sells is one part of Ultragenyx Pharmaceutical's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have RARE's insiders bought or sold?
From Jun 1, 2026 to Oct 19, 2026 Ultragenyx Pharmaceutical's insiders bought 0 and sold $655.0K of shares on the market. 76% of the sales were under set 10b5-1 plans.
Which well-known managers hold RARE?
7 of the managers we track held the shares on Sep 30, 2026. The largest position was Millennium Mgmt (Englander)'s, worth $23M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.